Formycon and Biocelys partner on biosimilar project FYB286

Formycon AG and Biocelys S.A. have announced a collaboration to develop the biosimilar candidate FYB286. The partnership aims to combine Formycon’s development expertise with the manufacturing infrastructure of Biocelys, a South American specialty pharmaceutical company.

The project is pre-financed by Santo Biosimilar GmbH, a company within the ATHOS Group. ATHOS serves as Formycon’s largest anchor shareholder and maintains indirect control over both Santo and Biocelys. Under the agreement, Formycon will receive market-standard compensation for development services and will hold a low double-digit percentage interest in future revenues from Santo.

FYB286 is intended to target a niche indication with high growth potential, serving as a strategic addition to Formycon’s existing biosimilar portfolio.